The current pandemic of COVID-19, with its climbing number of cases and deaths, has us searching for tools for rapid, reliable, and affordable methods of detection on one hand, and novel, improved therapeutic strategies on the other . The currently employed RT-PCR method, despite its all-encompassing utility, has its shortcomings . Newer diagnostic tools, based on the Clustered Regularly Interspaced Short Palindromic Repeats/Cas (CRISPR-Cas) system, with its better diagnostic accuracy measures, have come up to fill that void . These assay platforms are expected to slowly take up the place of COVID-19 diagnostics . Further, the current therapeutic options focus mainly on counteracting the viral proteins and components and their entry into host cells . The CRISPR-based system, especially through the RNA-guided Cas13 approach, can identify the genomic characteristics of SARS-CoV-2 and provide a novel inhibition strategy for coronaviruses . In this mini-review, we have discussed the available and upcoming CRISPR-based diagnostic assays and the potential of the CRISPR/Cas system as a therapeutic or prevention strategy in COVID-19 . CRISPR-Cas system shows promise in both diagnostics as well as therapeutics and may as well change the face of molecular diagnosis and precision medicine.